104 results
8-K
EX-99.1
CRVO
CervoMed Inc
12 Feb 21
Note Regarding Forward-looking Statements
8:19am
, including the recent U.S. presidential election;
the ongoing COVID-19 pandemic; and
other risks and uncertainties, including those discussed … crises such as the COVID-19 pandemic, could negatively affect our business and our operating results.
The COVID-19 pandemic has resulted in significant
8-K
EX-99.1
CRVO
CervoMed Inc
10 Aug 20
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
5:00pm
of the on-going pandemic. This program, featuring the PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC) trial, will ultimately involve a total of 23 … of Diffusion. “Given the severity of the worldwide pandemic, regulatory authorities in the U.S. and Europe have put in place measures to expedite the testing
8-K
EX-99.1
CRVO
CervoMed Inc
11 May 20
Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
4:58pm
in stroke was delayed by the pandemic, TSC’s novel hypoxia-treating mechanism of action allowed us to quickly pivot to treat ARDS in COVID-19 patients … of the pandemic and the pace of future enrollment in the PHAST-TSC study are unknown, our current cash position allows us to fund operations for at least
8-K
EX-99.1
53ougkrh
7 Jul 20
Phase 1b dosing expected to begin this month
4:38pm
8-K
EX-99.1
w0e8z
24 Mar 20
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
4:41pm
8-K
EX-99.1
98s5 ub1bb7tiygbjw
26 May 20
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
4:45pm
8-K
EX-99.1
9qxpv2y
29 Jul 20
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
8:14am
8-K
EX-99.1
v24nv5 ce1m
20 May 20
Other Events
5:27pm
8-K
EX-99.1
7a71qaezvjnisyo cug
12 Jun 20
Dosing expected to begin in Q2 2020 with first data in Q3 2020
12:18pm
8-K
EX-99.1
ubpwkf1 8tk
21 Mar 22
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
4:26pm
424B3
ngqr6 mgvs
8 Jun 20
Prospectus supplement
4:48pm
8-K
EX-99.1
f5c553zss82inj
13 Sep 21
Diffusion Pharmaceuticals Issues Letter to Shareholders
4:09pm
8-K
EX-99.2
pxfvyz7uminv
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-99.1
9xq mp0rva0q
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-99.1
hggaagljjwkgky0ou
4 Sep 20
Diffusion Pharmaceuticals Appoints
4:01pm
8-K
EX-99.1
q7bp9di8 yq
8 May 20
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
4:40pm